PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7998784

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SEAGULL THERAPEUTICS SAS	04/17/2023

RECEIVING PARTY DATA

Name:	GUIDO SERINI
Street Address:	STRADA CASTELVECCHIO 30
City:	MONCALIERI
State/Country:	ITALY
Postal Code:	10024
Name:	ENRICO GIRAUDO
Street Address:	VIA FIUME 13
City:	CIRIE
State/Country:	ITALY
Postal Code:	10073
Name:	LUCA TAMAGNONE
Street Address:	CORSO EINAUDI 43
City:	TORINO
State/Country:	ITALY
Postal Code:	10129

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	10906948

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (301) 675-1732

Email: patents@inhousepc.com

Correspondent Name: MICHELE WALES
Address Line 1: 9540 FIELDS ROAD

Address Line 4: GAITHERSBURG, MARYLAND 20878

PATENT REEL: 063906 FRAME: 0545

507951651

ATTORNEY DOCKET NUMBER:	SEA-01-US	
NAME OF SUBMITTER:	MICHELE WALES	
SIGNATURE:	/Michele Wales/	
DATE SIGNED:	06/09/2023	
Tatal Attachments A		

Total Attachments: 4

source=UP-1085-DOMAIN THERA - US Assignment and declaration#page1.tif source=UP-1085-DOMAIN THERA - US Assignment and declaration#page2.tif source=UP-1085-DOMAIN THERA - US Assignment and declaration#page3.tif source=UP-1085-DOMAIN THERA - US Assignment and declaration#page4.tif

PATENT REEL: 063906 FRAME: 0546

ASSIGNMENT AND DECLARATION FOR PATENT

WHEREAS, I (hereinafter referred to as the "ASSIGNOR"):

Name: Residing At:

850 Boulevard Sébastien Brant, Bioparc Seagull Therapeutics SAS

67400 Illkirch Graffenstaden / FR

Has previously obtained assignment of certain new and useful improvements in:

NON-NATURAL SEMAPHORINS 3 AND THEIR MEDICAL USE

As set forth in US Patent No. 10,906,948, issued on February 2, 2021 which claims priority to PCI/EP2016/053750 filed on February 23, 2016, which claims priority to EP 15156195.8 filed on February 23, 2015, and

WHEREAS, the following individuals (hereinafter each of which are referred to as "ASSIGNEE") located at the addresses listed below:

Guido Serini	Strada Castelvecchio 30 Moncalieri, TO 10024 Italy
Enrico Giraudo	via Fiume 13 Ciriè, TO 10073 Italy
Luca Tamagnone	Corso Einaudi 43 Torino, TO 10129 Italy

is desirous of acquiring the entire right, title and interest in and to said inventions and said Application for Letters Patent of the United States, and in and to any Letters Patent of the United States to be obtained therefore and thereon and in any and all foreign countries;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged,

> PATENT REEL: 063906 FRAME: 0547

Assignor sold, assigned, transferred and set over and hereby confirms any previous assignments, and by these presents do sell, assign, transfer and set over, unto Assignee, successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and application for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said application, and any and all Letters Patent in the United States which may be granted therefore and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for own use and benefit and the use and benefit of successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby represents and warrants to Assignee, successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignor is the sole and lawful owner of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignor good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, successors, legal representatives and assigns, that Assignor will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for

SEA-01-US

Letters Patent for said inventions including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable

AND Assignor hereby requests the Commissioner for Patents and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, successors, legal representatives and assigns.

SEAGULL THERAPEUTICS, SAS

Date: 17 12 12 12 12 12 13

<u>PALCAL NEUVICUE</u>

THILE

SEA-01-US

PATENT REEL: 063906 FRAME: 0550

RECORDED: 06/09/2023